CF lung inflammation persists after treatment due to stubborn bacteria
Persistent Pseudomonas aeruginosa infection in people with cystic fibrosis (CF) who have received treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) seems to be a main driver of lung inflammation, a new study found. Trikafta is a highly effective CFTR modulator. Researchers also observed an “all-or-none” pattern in infection clearance in most…